Combinations; Ketorolac eye drops- See below
Dosage ;
Dosing: Adult
Pain management (acute; moderately-severe):
Note: The maximum combined duration of treatment (for parenteral and oral) is 5 days; do not increase dose or frequency;
supplement with low dose opioids if needed for breakthrough pain.
For patients <50 kg and/or ≥65 years of age, see Elderly dosing.
I.M.: 60 mg as a single dose or 30 mg every 6 hours (maximum daily dose: 120 mg)
I.V.: 30 mg as a single dose or 30 mg every 6 hours (maximum daily dose: 120 mg)
Oral: 20 mg, followed by 10 mg every 4-6 hours; do not exceed 40 mg/day;
oral dosing is intended to be a continuation of I.M. or I.V. therapy only
Dosing: Pediatric
Pain management (acute; moderately-severe):
Children ≥16 years and <50 kg: I.V.: Refer to elderly dosing.
Children ≥16 years and ≥50 kg: I.V.: Refer to adult dosing.
Children ≥17 years and <50 kg: Oral: Refer to elderly dosing.
Children ≥17 years and ≥50 kg: Oral: Refer to adult dosing.
Dosing: Geriatric
Dosage adjustments in elderly (≥65 years), renal insufficiency, or low body weight (<50 kg):
Note: These groups have an increased incidence of GI bleeding, ulceration, and perforation. The maximum combined duration of treatment (for parenteral and oral) is 5 days.
I.M.: 30 mg as a single dose or 15 mg every 6 hours (maximum daily dose: 60 mg)
I.V.: 15 mg as a single dose or 15 mg every 6 hours (maximum daily dose: 60 mg)
Oral: 10 mg, followed by 10 mg every 4-6 hours;
do not exceed 40 mg/day; oral dosing is intended to be a continuation of I.M. or I.V. therapy only
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Rolac | Renata Limited | Unisel Pharma (K) Ltd. | 10mg | 20 | Tablet | per tablet | KES 1000.00 |
| Rolac | Renata Limited | Unisel Pharma (K) Ltd. | 30mg | 6 | Injection | per vial | KES 1,110.00 |
| Ketorolac trametamol eye drops | |
|---|---|
| Mode Of Action | Inhibitors of cyclo-oxygenase (COX-1 and COX-2) enzyme that catalyzes the conversion of arachidonic acid to PGH2 e.g. Aspirin |
| Drug Indication | Painful conditions requiring analgesia where NSAIDs are not contraindicated. |
| Drug Category | OPHTHALMIC DRUGS |
| Drug Sub-Category | other opthalmic drugs |
Ketorolac trametamol more info
| Mode Of Action | Inhibitors of cyclo-oxygenase (COX-1 and COX-2) enzyme that catalyzes the conversion of arachidonic acid to PGH2 e.g. Aspirin |
|---|---|
| Drug Indication | Painful conditions requiring analgesia where NSAIDs are not contraindicated. |
| Contra-Indications | Allergy to NSAIDs; bronchospasm; asthma; history of peptic ulceration or current ulceration episodes; nasal polyps; dehydration; hypovoleamia; moderate to severe renal disorders; coagulation or haemorrhagic disorders; patients on anticoagulants. |
| Side Effects | GI disturbances such as GI bleeding, perforation and peptic perforation; allergic reactions such as bronchospasm, laryngeal oedema, skin rash, hypotension and anaphylaxis; drowsiness. |
| Special Information | Its USAN name is ketorolac tromethamine and it is a pyrrolizine carboxylic acid derivative structurally related to indomethacin. |
| Pregnancy Category | Category D |
| Pregnancy Category Description | Drugs, which have caused, are suspected to have caused, or may be expected to cause an increased rise in the frequency of malformations or irreversible damage. These drugs may also have adverse pharmacological effects required required |
| Drug Category | DRUGS ACTING ON CNS |
| Drug Sub-Category | Analgesics, Antipyretics & NSAIDS |